Global Tachycardia Drugs Market, By Drugs (Lanoxin, Tapazole, Acetaminophen, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast thttps://www.databridgemarketresearch.com/reports/global-parenteral-nutrition-marketo 2029.
Tachycardia Drugs Market Analysis and Size
The global tachycardia drugs market is expected to witness significant growth during the forecast period. Cardiovascular diseases are one of the foremost causes of death globally. Factors such as increasing approvals for vascular closure devices, increasing demand for advanced treatment, increasing research and clinical trials for tachycardia, government initiatives and support, and rising market players offering newer products are likely to boost the market. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global tachycardia drugs market in the forecast period 2022-2029. The expected CAGR of global tachycardia drugs market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 12.5 billion in 2021, and it would grow upto USD 19.18 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Tachycardia is a type of medical condition when heartbeat is faster than normal. It only occurs during rest and affects both upper and lower chamber of the heart, mostly not causing any harm. Although, in some cases it can lead to several complications such as heart attack, stroke and heart failure. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Tachycardia Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Lanoxin, Tapazole, Acetaminophen, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Cadila Pharmaceuticals (India), Lilly (U.S.), Cipla Inc. (U.S.), Aurobindo Pharma (India), Lupin (India), ADVANZ PHARMA (U.K.), Avet Pharmaceuticals Inc. (U.S.)
|
|
Market Opportunities
|
|
Global Tachycardia Drugs Market Dynamics
Drivers
- Increase in Cardiovascular Diseases
According to the WHO, around 60% - 85% of population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 U.S. adults meets the appropriate need of physical activity. As a result, inotropic agents are used in this process. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of inotropic agents delivered through these retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Increased Use in Major Surgeries
In many major surgeries, anaesthetists commonly use various mild inotropic or vasopressor agents in huge doses to accurate the cardiovascular effects of general and regional anaesthesia. Ephedrine, phenylephrine and metaraminol are the most common options for this indication. In addition to this, inotropic agents are being widely chosen for haemodynamic therapy with pre-determined goals, that includes cardiac index, systemic oxygen delivery and/or venous saturation. This creates much opportunity for the market growth.
- Higher Demand of Blood Thinners
Blood thinners are demanded by the market on a great scale as a result of the growing cardiovascular disorders. Growing life expectancy of the aged population has enhanced the sales of cardiovascular drugs. The higher prevalence of cardiovascular disorders among the youngsters has heightened the sales of these emergency drugs. Hypertensive drugs cannot be withdrawn easily, which in return helps to continue the demand and supply of these drugs. These several factors provide great opportunities to the market.
Restraints/Challenges
- Complications of Tachycardia Drugs
Some common side effects of tachycardia drugs include lightheaded, dizzy, chest pain, heart palpitations, anxiety, fever. Thus, it creates hindrance to the market growth.
- High Cost
The high cost associated with the tachycardia drugs makes it non affordable for the poor people residing in the highly developing nations which impedes the growth of the market during the forecast period.
This global tachycardia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global tachycardia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Tachycardia Drugs Market
The covid-19 pandemic greatly impacted the global tachycardia drugs market because the utmost priority was given to Covid-19 patients for treatment. The COVID-19 pandemic caused a tremendous increase in its sales, as most of the population were stressed, with improper diet and minimal exercise. In addition to this, several tachycardia drugs were successful in treating many COVID-19 patients who were hospitalized. Thus, the COVID-19 outbreak increased the tachycardia drugs market’s growth globally.
Global Tachycardia Drugs Market Scope
The global tachycardia drugs market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Lanoxin
- Tapazole
- Acetaminophen
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Tachycardia Drugs Market Regional Analysis/Insights
The global tachycardia drugs market is analysed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global tachycardia drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high-income of the countries, favourable reimbursement and advanced healthcare facilities
Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Tachycardia Drugs Market Share Analysis
The global tachycardia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global tachycardia drugs market.
Key players operating in the global tachycardia drugs market include:
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (U.K.)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Cadila Pharmaceuticals (India)
- Lilly (U.S.)
- Cipla Inc. (U.S.)
- Aurobindo Pharma (India)
- Lupin (India)
- ADVANZ PHARMA (U.K.)
- Avet Pharmaceuticals Inc. (U.S.)
SKU-